Oct. 31, 2012 | Vol. 11 No. 214 | Full Issue in PDF Format
View the entire issue.
SEATTLE — The FDA’s Office of International Programs (OIP) is exploring development of a single, global recall system that would encompass all domestic and international recalls.
Dr. Reddy’s plans to key in on more complex generics such as injectables, particularly in the U.S. market, to help insulate its products from fierce competition.
GlaxoSmithKline (GSK) is moving its biologic mepolizumab forward, beginning two Phase III trials of the drug as an adjunct therapy in severe uncontrolled refractory asthma.
An independent analysis by the Alzheimer’s Disease Cooperative Study (ADCS) has found higher beta amyloid levels in the blood of patients treated with Eli Lilly’s Alzheimer’s candidate solanezumab compared with placebo.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.